Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/DDDT.S259058 http://scihub22266oqcxt.onion/10.2147/DDDT.S259058 32801640!7396737!32801640     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Des+Devel+Ther 2020 ; 14 (ä): 3001-3013 Nephropedia Template TP {{tp|p=32801640|t=2020. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients |pdf=|usr=}}{{32801640}} gab.com Text Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients JO: Drug Des Devel Ther http://www.kidney.de/pget.php?&tw=1&pmid=32801640 #FOAvip Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection. Twit Text FOAVip Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients ????Drug Des Devel Ther http://www.kidney.de/pget.php?&tw=1&pmid=32801640 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32801640 #FOAvip English Wikipedia <ref>{{Cite pmid|32801640}}</ref> Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients #MMPMID32801640 Li L; Wang X; Wang R; Hu Y; Jiang S; Lu X Drug Des Devel Ther 2020[]; 14 (ä): 3001-3013 PMID32801640show ga Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection. |Aged[MESH] |Antiviral Agents/adverse effects/pharmacokinetics/*pharmacology[MESH] |Betacoronavirus/drug effects/isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/epidemiology/virology[MESH] |Critical Illness[MESH] |Female[MESH] |Humans[MESH] |Kidney Diseases/complications[MESH] |Liver Diseases/complications[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/virology[MESH] |Pregnancy[MESH]Antiviral Agent Therapy Optimization in Special Populations of COVID-1(epmc).pdf DeepDyve Pubget Overpricing